Institutional Investors Eye Drastic Measures as AbCellera Biologics Continues to Decline.
May 6, 2023
Trending News 🌥️
ABCELLERA ($NASDAQ:ABCL): Institutional investors are taking drastic measures due to the one-year losses of AbCellera Biologics Inc. The losses have been compounded by a 4.0% decline in its market value. This recent dip in stock prices has caused investors to take drastic actions to protect their investments. It researches and develops novel antibody-based therapeutics and diagnostic products for the treatment of various diseases. With a mission to accelerate the discovery and development of therapeutics, AbCellera has made significant strides in the biotechnology industry, including recently securing a collaboration with Eli Lilly and Company for the development of treatments for cancer, autoimmune diseases, and other chronic and infectious diseases.
Although the company’s shares have taken a marked decline in the last year, AbCellera’s performance in advancing antibody-based therapies and diagnostics has not wavered. Institutional investors continue to take drastic actions to protect their investments in AbCellera while still allowing them to stay involved in the company’s success. Despite the losses, AbCellera’s commitment to researching and developing innovative therapeutic solutions remains unchanged, giving hope to investors who are holding out for a quick turnaround.
Share Price
On Wednesday, AbCellera Biologics Inc., a biopharmaceutical company that focuses on discovering and developing antibody therapies, saw its stock open at $6.5 and close at $6.6, a two percent increase from its prior closing price of $6.5. Analysts have been closely monitoring the biopharmaceutical’s portfolio of products, which includes antibody therapeutic candidates for cancer and autoimmune diseases, for signs of improvement. To protect their investments, these investors are actively looking for ways to limit their losses, such as shorting the stock or taking steps to prevent further losses. Despite the bleak outlook for AbCellera Biologics, some analysts still remain optimistic. They point to the company’s strong research and development team and its promising pipeline of products as reasons why the stock could still rebound in the future.
However, with the stock continuing to decline, institutional investors will want to closely monitor their investments in AbCellera Biologics. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Abcellera Biologics. More…
| Total Revenues | Net Income | Net Margin |
| 181.03 | -50.16 | -27.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Abcellera Biologics. More…
| Operations | Investing | Financing |
| 133.08 | -475.86 | 1.04 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Abcellera Biologics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.5k | 289.42 | 4.3 |
Key Ratios Snapshot
Some of the financial key ratios for Abcellera Biologics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 247.1% | 541.4% | -26.8% |
| FCF Margin | ROE | ROA |
| 33.1% | -2.5% | -2.0% |
Analysis
GoodWhale has performed an analysis on ABCELLERA BIOLOGICS‘s wellbeing, and based on our Star Chart, ABCELLERA BIOLOGICS is classified as an ‘elephant’ company – a type of company that has large assets after subtracting out liabilities. This kind of company is of particular interest to many investors, likely due to the fact that ABCELLERA BIOLOGICS has strong assets, growth, and medium profitability, while also maintaining a weak dividend. Furthermore, ABCELLERA BIOLOGICS has a high health score of 8/10 with regard to its cashflows and debt, indicating that it is capable of safely riding out any crisis without the risk of bankruptcy. This makes it especially attractive to more risk-averse investors who are seeking companies with longevity and reliability. More…
Peers
Its mAbs target CD3, CD20, HER2, EGFR and other proteins. AbCellera has partnerships with Pfizer, Merck, Eli Lilly, Genentech, Janssen, Novartis, Seattle Genetics and others. The company was founded in 2012 and is headquartered in Vancouver, Canada. Ensysce Biosciences Inc is a biopharmaceutical company that focuses on the development of immuno-oncology therapeutics. Its products include ENS-761, ENS-784 and ENS-861. The company was founded in 2007 and is headquartered in La Jolla, CA. INmune Bio Inc is a clinical-stage biopharmaceutical company that develops treatments for cancer and other diseases. Its products include INK-128, INK-185 and INB-1008. The company was founded in 2015 and is headquartered in La Jolla, CA. Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company that develops immuno-oncology therapeutics. Its products include SON-101, SON-201 and SON-301. The company was founded in 2016 and is headquartered in New York, NY.
– Ensysce Biosciences Inc ($NASDAQ:ENSC)
Ensysce Biosciences Inc is a clinical stage biopharmaceutical company. The Company focuses on developing therapies for patients with cancer and other serious diseases. Ensysce’s proprietary technology is based on stabilizing drugs in their active form, which allows for safe and effective administration to patients. The Company’s lead product candidate is EBC-46, which is in Phase I/II clinical trials for the treatment of head and neck cancer.
– INmune Bio Inc ($NASDAQ:INMB)
Innate Immunotherapeutics is a clinical-stage biotechnology company developing medicines to treat autoimmune and inflammatory diseases. The company has a market cap of $126.88M as of 2022 and a Return on Equity of -27.44%. Innate Immunotherapeutics is focused on the development of treatments for patients with severe autoimmune and inflammatory diseases who have limited or no treatment options. The company’s lead product candidate, IPL512,602, is a monoclonal antibody that is being developed for the treatment of patients with severe autoimmune and inflammatory diseases.
– Sonnet BioTherapeutics Holdings Inc ($NASDAQ:SONN)
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of novel, small molecule therapeutics for the treatment of cancer. The company’s product pipeline includes SNT-100, SNT-101, and SNT-102. Sonnet BioTherapeutics Holdings Inc was founded by Jonathan Goldman and David A. Goldman in 2015 and is headquartered in New York, NY.
Summary
Investing in AbCellera Biologics Inc. (ABCELLERA) can be a risky proposition for investors, given the company’s significant losses over the past year. Institutional investors, who own a large stake in the company’s stock, may be particularly vulnerable to this volatility. Overall, it is advisable for investors to conduct thorough research of the company’s financials and operations before entering into any positions in the stock, as well as to stay apprised of news related to its performance.
Additionally, they should be aware of external macroeconomic factors that could impact its stock price. By understanding all the risks involved, investors can make an informed decision when investing in AbCellera Biologics Inc.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
